ObjectiveTo analyze the clinical and immunological characteristics of 26 patients with antiphospholipid syndrome (APS). MethodsThe clinical and immunological features of APS in 26 patients treated between January 2009 and January 2012 were analyzed retrospectively. ResultsThe study consisted of 8 male and 18 female patients with a mean age of 38 years at diagnosis. Seven patients had primary APS. Nineteen patients had APS associated with autoimmune diseases, including 11 cases of systemic lupus erythematosus. Seventy-five percent of the patients had thrombosis, 16 had venous thrombosis, 7 had arterial thrombosis, and 2 had both arterial and venous thrombosis. The deep veins of the lower limbs and the cerebral arterial circulation were the most common sites of venous and arterial thrombosis. Fetal morbidity rate of 16 married women in our study was 43.8%. Thrombocytopenia and anemia were present in 57.7% and 69.2% of the patients respectively. ConclusionAPS is characterized by recurrent thrombosis, pregnancy morbidity and positive antiphospholipid antibodies tests. Early diagnosis and management is essential for APS.
ObjectiveTo explore the clinical manifestations, pathogenesis, prognosis and the therapeutic modalities of the patients with solid tumors combined with remarkable hematologic abnormalities. MethodsGastric cancer in a paitnet was diagnosed by endoscopy as well as pathological biopsy and myeloproliferative neoplasms (MPNs) were excluded through bone marrow examinations. Therefore, the primary and metastatic malignancies were excised. ResultsAlthough surgical operation improved the hematologic changes, the high tumor load caused the poor prognosis. ConclusionThe solid tumors may present with hematologic manifestations which is similar to the symptoms of MPNs; it belongs to the para-neoplastic phenomenon and may be an independent poor prognostic factors.
ObjectiveTo systematically review the effects of Liujunzi decoction on improving the quality of life (QOL) of patients with advanced primary liver cancer. MethodsDatabases including MEDLINE, EMbase, SCI, The Cochrane Library (Issue 2, 2014), CBM, CNKI, VIP and WanFang Data were searched electronically from inception to July 2014 to collect randomized controlled trials (RCTs) about Liujunzi Decoction for advanced primary liver cancer. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed by using RevMan 5.3 software. ResultsA total of 7 RCTs involving 458 patients were included. The results of meta-analysis showed that the Liujunzi decoction group had significantly higher stability of QOL (RR=0.76, 95%CI 0.64 to 0.91, P=0.002), Karnofsky Performance Score (KPS) (MD=4.47, 95%CI 2.74 to 6.21, P<0.00001) and effective rate of TCM syndrome (RR=0.73, 95%CI 0.62 to 0.86, P=0.0001) than those of the control group. ConclusionCurrent evidence shows that Liujunzi decoction could improve the QOL and KPS, and relieve TCM syndromes of patients with advanced primary liver cancer, especially for those with spleen deficiency-syndrome. Due to the limited quantity and quality of the included studies, the above conclusion still needs to be verified by carrying out more high-quality RCTs.